TRACON Pharmaceuticals
2:30 PM - 2:45 PM (EST), Monday, February 6, 2023 ・ Music Box
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. Our other product candidates are YH001, a CTLA-4 antibody that is in Phase 1/2 development for the treatment of sarcoma, TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase 1 testing, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.
Ticker:
TCON
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Envafolimab
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One
Speaker
